Systematic Reviews
Copyright ©The Author(s) 2022.
World J Virol. Sep 25, 2022; 11(5): 375-390
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.375
Table 3 Summary of studies characterizing the role of novel biomarkers in prognosis and outcomes in COVID-19
Biomarker in COVID
Study
Recommendation
PresepsinFavaloro et al[73]Presepsin elevation is a reliable biomarker in COVID-19
Park et al[74]A four-to-five-fold increase in presepsin correlates with disease severity in COVID-19
Lippi et al[75]
Koyjit et al[73]
Fukada et al[77]Presepsin is elevated in severe cases of SARS-CoV-2 associated respiratory complications
Park et al[74]Presepsin level at 717pg/ml is a significant predictor of 30-day mortality
Dell’Aquila et al[79]A threefold rise in presepsin has been identified as a very specific indicator of 30-day mortality
Lippi et al[75]
Soluble ST2 (sST2)Omland et al[87]Robust association between baseline sST2 level and disease severity along with poor outcome
Huang et al[88]Baseline sST2 is associated with a worse prognosis
Ragusa et al[89]Circulating level of sST2 can be used as a discharge prognosticator
Galectin-3Caniglia et al[96]Gal-3 is considerably higher in bronchoalveolar immune cells in patients with severe COVID-19 disease
Portacci et al[97]Higher galectin-3 is associated with worse outcomes and shorter survival
CopeptinGregoriano et al[100]Serum copeptin level above 20 Pmol/L had sensitivity of > 88% to predict severe COVID-19
Hammad et al[101]Serum copeptin level above 18.5 Pmol/L had sensitivity of > 93% and specificity of 100% to predict severe COVID-19
GDF 15Apfel et al[103]Higher levels of GDF-15 correlated with severity of COVID-19